Skip to main content

Table 3 Severity and QOL scores during sirolimus treatment

From: The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies

 

Severity score

QOL score

All score

Physical score

Psychological score

Pretreatment

6 months

p valuea

Pretreatment

6 months

p valuea

Pretreatment

6 months

p valuea

Pretreatment

6 months

p valuea

All patients (n = 20)

8.0 (3–20)

5.0 (1–20)

0.0029

58.1 (17.4–94.6)

77.3 (7.7–91.3)

0.0129

50.0 (0–100)

77.6 (0–100)

0.0105

65.0 (12.5–100)

75.8(16.7–100)

0.0052

PR patients (n = 10)

8.0 (3–13)

4.5 (1–7)

0.0020

58.1 (17.4–84.7)

76.2 (51.1–91.3)

0.0117

48.4 (18.8–98.4)

77.6 (21.9–98.4)

0.0078

65.0 (12.5–78.1)

75.8 (60–90.5)

0.0156

SD patients (n = 10)

6.5 (3–20)

5.5 (1–20)

0.4375

63.3 (23.9–94.6)

79.8 (7.7–91.3)

0.3828

53.1 (0–100)

69.5 (0–100)

0.367

67.5 (27.5–-100)

82.5 (16.7–100)

0.2188

  1. Values presented as median (range)
  2. PR partial response, SD stable disease
  3. aWilcoxon signed rank test for comparison between pretreatment and 6 months